TITLE

A randomised controlled trial of total immunosuppression withdrawal in stable liver transplant recipients

AUTHOR(S)
Assy, N.; Adams, P. C.; Myers, P.; Simon, V.; Ghent, C. N.
PUB. DATE
February 2007
SOURCE
Gut;Feb2007, Vol. 56 Issue 2, p304
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article discusses a randomised controlled study of total immunosuppression withdrawal in stable liver transplant recipients. Results showed that late total immunosuppression withdrawal in stable liver transplant recipients is safe but seldom successful and most useful for patients transplanted for autoimmune liver disease. The authors suggest that the search for a means of identifying allograft tolerance among immunesuppressed recipients should become a priority in liver transplantation.
ACCESSION #
24040278

 

Related Articles

  • Transplantation in autoimmune liver diseases. Mottershead, Marcus; Neuberger, James // World Journal of Gastroenterology;6/7/2008, Vol. 14 Issue 21, p3388 

    Liver transplantation remains an effective treatment for those with end-stage disease and with intractable liver-related symptoms. The shortage of organs for transplantation has resulted in the need for rationing. A variety of approaches to selection and allocation have been developed and vary...

  • High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis? Berardi, S.; Lodato, F.; Gramenzi, A.; D'Errica, A.; Lenzi, M.; Bontadini, A.; Morelli, M. C.; Tamè, M. R.; Piscaglia, F.; Biselli, M.; Sama, C.; Mazzella, G.; Pinna, A. D.; Grazi, G.; Bernardi, M.; Andreone, P. // Gut;Feb2007, Vol. 56 Issue 2, p237 

    Background: Interferon may trigger autoimmune disorders, including autoimmune hepatitis, in immunocompetent patients. To date, no such disorders have been described in liver transplanted patients. Methods: 9 of 44 liver transplanted patients who had been receiving pegylated-interferon alpha-2b...

  • Tacrolimus: A Potential New Treatment for Autoimmune Chronic Active Hepatitis: Results of an Open-Label Preliminary Trial. Van Thiel, David H.; Wright, Harlan; Carroll, Patricia; Abu-Elmagd, Kareem; Rodriguez-Rilo, Horacio; McMichael, John; Irish, William; Starzl, Thomas E. // American Journal of Gastroenterology;May1995, Vol. 90 Issue 5, p771 

    Autoimmune chronic active hepatitis (CAH-A) is a chronic liver disease of unknown etiology that is believed to have an autoimmune pathogenesis. The disease is slowly progressive until hepatic failure and portal hypertension develop and either death or liver transplantation occur. Currently, the...

  • Post-transplant lymphoproliferative disease in liver transplantation. M S Dhillon; J K Rai; B K Gunson; S Olliff; J Olliff // British Journal of Radiology;May2007, Vol. 80 Issue 953, p337 

    Post-transplant lymphoproliferative disease (PTLD) is a well recognized complication of solid organ transplantation and therapeutic immunosuppression, first reported in 1968. PTLD incorporates a spectrum of abnormalities ranging from a benign infectious mononucleosis-like illness to...

  • Nutrition and Growth in Children with Chronic Liver Disease and After Liver Transplantation. Taylor, Rachel M.; Dhawan, Anil // Current Nutrition & Food Science;2006, Vol. 2 Issue 2, p107 

    Malnutrition is a common complication of chronic liver disease (CLD). Standard anthropometric techniques available to assess nutritional status in children with CLD are noted to be inadequate but more sophisticated methods are all limited to research. Nutritional interventions in a few case...

  • Analysis of Postsurgical Complications in 75 Living Liver Transplantation Donors Sozen, Hakan; Karakayali, Hamdi; Moray, Gokhan; Dalgic, Aydin; Emiroglu, Remzi; Haberal, Mehmet // Journal of Gastrointestinal Surgery;May2006, Vol. 10 Issue 5, p646 

    Seventy-five living donor liver hepatectomies were performed at our transplantation center between April 1990 and December 2004. We collected the data from patient charts, files, and the Baskent University Liver Registry. There were 39 male and 36 female donors (mean age, 35.1 ± 9.3 years)....

  • Pregnancy after liver transplantation: Four-year follow-up of the first case in mainland China. Dong Xia; Hong-Yuan He; Liang Xu; Yi Quan; Huai-Quan Zuo; Lu-Nan Yan; Bo Li; Yong Zeng; Guang-Dong Pan; Razonable, Raymund R. // World Journal of Gastroenterology;12/21/2008, Vol. 14 Issue 47, p7264 

    The safety and feasibility of pregnancy following liver transplantation (LT) have been accredited in a series of LT center. The first case in mainland China is reported. The follow-up data of a 22-year-old pregnant patient with end-stage liver disease undergone orthotopic liver transplantation...

  • Primary biliary cirrhosis. Kumagi, Teru; Heathcote, E. Jenny // Orphanet Journal of Rare Diseases;2008, Vol. 3, Special section p1 

    Primary biliary cirrhosis (PBC) is a chronic and slowly progressive cholestatic liver disease of autoimmune etiology characterized by injury of the intrahepatic bile ducts that may eventually lead to liver failure. Affected individuals are usually in their fifth to seventh decades of life at...

  • Autoimmune paediatric liver disease. Mieli-Vergani, Giorgina; Vergani, Diego // World Journal of Gastroenterology;6/7/2008, Vol. 14 Issue 21, p3360 

    Liver disorders with a likely autoimmune pathogenesis in childhood include autoimmune hepatitis (AIH), autoimmune sclerosing cholangitis (ASC), and de novo AIH after liver transplantation. AIH is divided into two subtypes according to seropositivity for smooth muscle and/or antinuclear antibody...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics